Rilonacept (interleukin‐1 trap) for prevention of gout flares during initiation of uric acid–lowering therapy: Results from a phase III randomized, double‐blind, placebo‐controlled, confirmatory efficacy study

安慰剂 医学 痛风 尿酸 双盲 药理学 内科学 替代医学 病理
作者
H. Ralph Schumacher,Robert R. Evans,Kenneth G. Saag,James W. Clower,William Jennings,Steven P. Weinstein,George D. Yancopoulos,Jian Wang,Robert Terkeltaub
出处
期刊:Arthritis Care and Research [Wiley]
卷期号:64 (10): 1462-1470 被引量:113
标识
DOI:10.1002/acr.21690
摘要

Abstract Objective To evaluate the efficacy and safety of the interleukin‐1 inhibitor rilonacept (interleukin‐1 Trap) for gout flare prevention during initiation of uric acid–lowering therapy (ULT). Methods In total, 241 adult patients with gout, ≥2 gout flares within the past year, and a serum urate level ≥7.5 mg/dl were initiated on allopurinol 300 mg daily and randomly allocated in a 1:1:1 ratio to receive 16 once‐weekly subcutaneous injections of placebo, rilonacept 80 mg, or rilonacept 160 mg, with a double (loading) dose on day 1. Allopurinol was titrated to achieve a serum urate level of <6.0 mg/dl. The study was powered for the primary efficacy end point, the number of gout flares per patient through week 16. Results More patients in the rilonacept groups (80.0% in the rilonacept 80 mg group, 86.4% in the rilonacept 160 mg group) completed the study than in the placebo group (72.5%; P < 0.05 for the rilonacept 160 mg group versus the placebo group). Over 16 weeks, the mean number of gout flares per patient was significantly reduced by rilonacept treatment (placebo: 1.06, rilonacept 80 mg: 0.29 [ P < 0.001], rilonacept 160 mg: 0.21 [ P < 0.001]). Significantly lower proportions of patients reported ≥1 gout flares with rilonacept 80 mg (18.8%) and rilonacept 160 mg (16.3%) relative to placebo (46.8%; P < 0.001 for both). Except for injection site reactions (1.3% in the placebo group versus 8.8% in the rilonacept 80 mg group [ P = 0.0635, post hoc analysis] and 19.8% in the rilonacept 160 mg group [ P = 0.0001, post hoc analysis]), the incidence of adverse events was generally balanced among the treatment groups. Conclusion Rilonacept markedly reduced the occurrence of gout flares associated with the initiation of ULT. The efficacy and safety profile suggests that rilonacept may have the potential to improve long‐term disease control for some patients by improving adherence to ULT by reducing flares during the first months after ULT initiation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Scofield完成签到 ,获得积分10
1秒前
吃花生酱的猫完成签到,获得积分10
2秒前
CJX完成签到,获得积分10
3秒前
赵正洁完成签到,获得积分10
4秒前
科研顺利完成签到,获得积分10
5秒前
Pan发布了新的文献求助10
5秒前
契说完成签到 ,获得积分10
8秒前
人间慈悲的应助被初一采纳,获得10
9秒前
lee完成签到,获得积分10
9秒前
力力不吃芒果完成签到 ,获得积分10
9秒前
Ren的应助被daomaihu采纳,获得100
9秒前
Ren的应助被daomaihu采纳,获得100
9秒前
orixero的应助被ZZ采纳,获得10
10秒前
Maestro_S的应助被哇啦采纳,获得10
11秒前
12秒前
13秒前
人间慈悲的应助被典雅依玉采纳,获得10
13秒前
13秒前
KFY完成签到,获得积分10
13秒前
14秒前
JJSA完成签到,获得积分10
15秒前
慕青的应助被SOBER采纳,获得10
15秒前
17秒前
娜比完成签到,获得积分10
17秒前
丘比特的应助被lsq108采纳,获得10
17秒前
18秒前
ZZL发布了新的文献求助10
18秒前
yuyu发布了新的文献求助10
19秒前
22秒前
22秒前
22秒前
在水一方的应助被科研通管家采纳,获得10
22秒前
大模型的应助被科研通管家采纳,获得10
23秒前
彭于晏的应助被科研通管家采纳,获得10
23秒前
我是老大的应助被科研通管家采纳,获得10
23秒前
小蘑菇的应助被科研通管家采纳,获得10
23秒前
Firsterchao的应助被科研通管家采纳,获得10
23秒前
pap发布了新的文献求助10
23秒前
天天快乐的应助被科研通管家采纳,获得10
23秒前
syvshc的应助被科研通管家采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186806
求助须知:如何正确求助?哪些是违规求助? 9575125
关于积分的说明 21839712
捐赠科研通 7784453
什么是DOI,文献DOI怎么找? 3434839
关于科研通互助平台的介绍 2559245
邀请新用户注册赠送积分活动 2481712